Cómo citar
1.
Villanea CF. Terapia de reemplazo hormonal: ventana de oportunidad. Rev.méd.sinerg. [Internet]. 1 de enero de 2019 [citado 23 de abril de 2024];4(1):14 - 22. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/166
Resumen
Se exhibirá una revisión sobre la terapia de reemplazo hormonal (TRH), tratando de promover los criterios de “la ventana de oportunidad”, con la finalidad de determinar cuáles mujeres son ideales para recibir dicha terapia de manera útil, responsable y segura. Asimismo, se contará con una explicación de la evolución desde los inicios hasta la actualidad de la TRH. Se pondrá a la vista del lector algunos principios primordiales sobre el uso adecuado de la terapia. También, se contará con una discusión sobre los beneficios de su uso sobre la salud de la mujer postmenopáusica y sus potenciales efectos secundarios. Se finalizará aclarando que la TRH utilizando los criterios de “la ventana de oportunidad” es una manera de asegurar una vida digna para las mujeres postmenopáusicas, sabiendo que en la actualidad no existe una TRH ideal, es y será un tema polémico con múltiples aristas.
Palabras clave
Terapia de reemplazo de hormonas. estrógenos. postmenopausia. climatoterapia.
Citas
1. Fritz MA, Speroff L. Endocrinología Ginecológica Clínica y Esterilidad. 8 Ed.. Lippincott Williams & Wilkins; 2011.
2. Vermeulen RF, Beurden MV, Kieffer JM, Bleiker EM, Valdimarsdottir HB, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten HW, Aaronson NK. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. European Journal of Cancer. 2017 Oct;84:159-167. https://doi.org/10.1016/j.ejca.2017.07.018
3. Clinical Guideline on Management of Menopausal Symptoms.www.aafp.org/afp/2014/0901/p338.html#. Accessed 2014 Septiembre 01.
4. Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecologic Oncology. 2016 01;140(1):101-106. https://doi.org/10.1016/j.ygyno.2015.11.016
5. Sturdee DW, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011 05 13;14(3):302-320. https://doi.org/10.3109/13697137.2011.570590
6. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012 05 22;15(3):217-228. https://doi.org/10.3109/13697137.2012.656401.
7. Campodónico I. Historia crítica de las terapias de reemplazo hormonal. Una visión particular después del estudio WHI. Rev. Obstet. Ginecol.- Hosp. Santiago Oriente Dr. Luis Tisné Brousse. 2018;13(01):51-53.
8. Hsia J. Conjugated Equine Estrogens and Coronary Heart Disease. Archives of Internal Medicine. 2006 02 13;166(3):357. https://doi.org/10.1001/archinte.166.3.357
9. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA. 2004 04 14;291(14):1701. https://doi.org/10.1001/jama.291.14.1701
10. Jalava-Broman J, Mäkinen J, Sillanmäki L, Vahtera J, Rautava P. Characteristics associated with initiation of hormone replacement therapy among Finnish women: A register-linkage study. Maturitas. 2016 07;89:73-78. https://doi.org/10.1016/j.maturitas.2016.04.011
11. Agarwal S, Alzahrani F, Ahmed A. Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?. International Journal of Molecular Sciences. 2018 Oct 14;19(10):3160. https://doi.org/10.3390/ijms19103160
12. Toh S. Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?. Annals of Internal Medicine. 2010 02 16;152(4):211. https://doi.org/10.7326/0003-4819-152-4-201002160-00005
13. Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertility and Sterility. 2016 Dec;106(7):1580-1587. https://doi.org/10.1016/j.fertnstert.2016.09.018
14. 14. Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G, Lopez S, Montera R, Gatti A, Serra GB, Benedetti Panici P, Terranova C. Hormone replacement therapy in cancer survivors: Utopia?. Critical Reviews in Oncology/Hematology. 2018 04;124:51-60. https://doi.org/10.1016/j.critrevonc.2018.02.005
15. O’Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynaecological malignancy. Current Opinion in Obstetrics and Gynecology. 2016 02;28(1):32-41. https://doi.org/10.1097/gco.0000000000000238
2. Vermeulen RF, Beurden MV, Kieffer JM, Bleiker EM, Valdimarsdottir HB, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten HW, Aaronson NK. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. European Journal of Cancer. 2017 Oct;84:159-167. https://doi.org/10.1016/j.ejca.2017.07.018
3. Clinical Guideline on Management of Menopausal Symptoms.www.aafp.org/afp/2014/0901/p338.html#. Accessed 2014 Septiembre 01.
4. Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecologic Oncology. 2016 01;140(1):101-106. https://doi.org/10.1016/j.ygyno.2015.11.016
5. Sturdee DW, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011 05 13;14(3):302-320. https://doi.org/10.3109/13697137.2011.570590
6. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012 05 22;15(3):217-228. https://doi.org/10.3109/13697137.2012.656401.
7. Campodónico I. Historia crítica de las terapias de reemplazo hormonal. Una visión particular después del estudio WHI. Rev. Obstet. Ginecol.- Hosp. Santiago Oriente Dr. Luis Tisné Brousse. 2018;13(01):51-53.
8. Hsia J. Conjugated Equine Estrogens and Coronary Heart Disease. Archives of Internal Medicine. 2006 02 13;166(3):357. https://doi.org/10.1001/archinte.166.3.357
9. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA. 2004 04 14;291(14):1701. https://doi.org/10.1001/jama.291.14.1701
10. Jalava-Broman J, Mäkinen J, Sillanmäki L, Vahtera J, Rautava P. Characteristics associated with initiation of hormone replacement therapy among Finnish women: A register-linkage study. Maturitas. 2016 07;89:73-78. https://doi.org/10.1016/j.maturitas.2016.04.011
11. Agarwal S, Alzahrani F, Ahmed A. Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?. International Journal of Molecular Sciences. 2018 Oct 14;19(10):3160. https://doi.org/10.3390/ijms19103160
12. Toh S. Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?. Annals of Internal Medicine. 2010 02 16;152(4):211. https://doi.org/10.7326/0003-4819-152-4-201002160-00005
13. Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertility and Sterility. 2016 Dec;106(7):1580-1587. https://doi.org/10.1016/j.fertnstert.2016.09.018
14. 14. Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G, Lopez S, Montera R, Gatti A, Serra GB, Benedetti Panici P, Terranova C. Hormone replacement therapy in cancer survivors: Utopia?. Critical Reviews in Oncology/Hematology. 2018 04;124:51-60. https://doi.org/10.1016/j.critrevonc.2018.02.005
15. O’Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynaecological malignancy. Current Opinion in Obstetrics and Gynecology. 2016 02;28(1):32-41. https://doi.org/10.1097/gco.0000000000000238
Descargas
Los datos de descargas todavía no están disponibles.